[go: up one dir, main page]

PE20010299A1 - DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5 - Google Patents

DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5

Info

Publication number
PE20010299A1
PE20010299A1 PE2000000672A PE0006722000A PE20010299A1 PE 20010299 A1 PE20010299 A1 PE 20010299A1 PE 2000000672 A PE2000000672 A PE 2000000672A PE 0006722000 A PE0006722000 A PE 0006722000A PE 20010299 A1 PE20010299 A1 PE 20010299A1
Authority
PE
Peru
Prior art keywords
decahydroisoquinoline
methyl
carboxyl
acid
derivatives
Prior art date
Application number
PE2000000672A
Other languages
English (en)
Inventor
David Bleakman
Amy Suzon Chappell
Paul Leslie Ornstein
Kirk Willis Johnson
Sandra Ann Filla
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20010299A1 publication Critical patent/PE20010299A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE AL USO DE UN ANTAGONISTA DEL RECEPTOR iGLUR5 TAL COMO EL ACIDO 3S,4aR,6S,8aR-6-(((4-CARBOXI)FENIL)METIL)-1,2,3,4,4a,5,6,7,8,8a-DECAHIDROISOQUINOLINA-3-CARBOXILICO, ACIDO 3S,4aR,6S,8aR-6-((((1H-TETRAZOL-5-IL)METIL)OXI)METIL)-1,2,3,4,4a,5,6,7,8,8a-DECAHIDROISOQUINOLINA-3-CARBOXILICO, 3S,4aR,6S,8aR, ETIL-6-(((2S)-2-(ETOXICARBONIL)-4,4-DIFLUOROPIRROLIDINIL)METIL-1,2,3,4,4a,5,6,7,8,8a-DECAHIDROISOQUINOLINA-3-CARBOXILATO DE ETILO; ACIDO 3S,4aR,6S,8aR-6-(((2S)-2-(ACIDO CARBOXILICO)-4,4-DIFLUOROPIRROLIDINIL)METIL)1,2,3,4,4a,5,6,7,8,8a-DECAHIDROISOQUINOLINA-3-CARBOXILICO; ENTRE OTROS; TAMBIEN SE REFIERE A UN COMPUESTO ISOQUINOLINA DE FORMULA I, DONDE: R1 Y R2 SON H, ALQUILO C1-C20, ALQUENILO C2-C6, ENTRE OTROS. EL ANTAGONISTA DEL RECEPTOR DE CAINATO DE BAJA INTENSIDAD iGLUR5 PUEDE SER UTIL PARA EL TRATAMIENTO DE LA MIGRANA
PE2000000672A 1999-07-06 2000-07-04 DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5 PE20010299A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27

Publications (1)

Publication Number Publication Date
PE20010299A1 true PE20010299A1 (es) 2001-03-07

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000672A PE20010299A1 (es) 1999-07-06 2000-07-04 DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5

Country Status (28)

Country Link
US (4) US6566370B1 (es)
EP (1) EP1200073B1 (es)
JP (1) JP4619595B2 (es)
KR (1) KR20020024300A (es)
CN (1) CN1230174C (es)
AR (1) AR029373A1 (es)
AU (1) AU773304B2 (es)
BR (1) BR0012175A (es)
CA (1) CA2378613C (es)
CZ (1) CZ20014488A3 (es)
DE (1) DE60032905T2 (es)
DK (1) DK1200073T3 (es)
DZ (1) DZ3209A1 (es)
EA (1) EA004290B1 (es)
ES (1) ES2278619T3 (es)
HK (1) HK1047036A1 (es)
HR (1) HRP20020013A2 (es)
HU (1) HUP0202253A3 (es)
IL (1) IL146697A0 (es)
MX (1) MXPA01012726A (es)
MY (1) MY133503A (es)
NO (1) NO20016246L (es)
NZ (1) NZ515616A (es)
PE (1) PE20010299A1 (es)
PT (1) PT1200073E (es)
SK (1) SK112002A3 (es)
TR (1) TR200200066T2 (es)
WO (1) WO2001001972A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046173A1 (en) * 1999-12-22 2001-06-28 Eli Lilly And Company SELECTIVE iGLUR5 RECEPTOR ANTAGONISTS
US6855725B2 (en) * 2001-01-05 2005-02-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP1351951A2 (en) * 2001-01-05 2003-10-15 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
ES2306690T3 (es) * 2001-01-05 2008-11-16 Eli Lilly And Company Antagonistas de receptores de aminoacidos excitatorios.
DZ3460A1 (fr) * 2001-01-05 2002-07-11 Lilly Co Eli Antagonistes du recepteur d'acide amine excitateur
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
AU2003226277B2 (en) 2002-04-26 2009-03-26 Eli Lilly And Company Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgesics
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
NZ575652A (en) 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ES2375417T3 (es) 2006-11-28 2012-02-29 Valeant Pharmaceuticals International Análogos 1,4-diamino bicíclicos de retigabina como moduladores de los canales de potasio.
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
KR20250048143A (ko) 2017-07-31 2025-04-07 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
CN120329431A (zh) 2018-03-05 2025-07-18 詹森药业有限公司 检测神经退行性变的测定
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
PH12022551110A1 (en) 2019-11-08 2024-02-26 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
EP4291189A1 (en) 2021-02-09 2023-12-20 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
JP2001521505A (ja) * 1997-04-07 2001-11-06 イーライ・リリー・アンド・カンパニー 薬理学的物質
ES2198323T3 (es) 1999-07-06 2004-02-01 Eli Lilly And Company Profarmacos de diesteres de un acido decahidroisoquinolin-3-carboxilico.

Also Published As

Publication number Publication date
US20050159445A1 (en) 2005-07-21
EA200200132A1 (ru) 2002-06-27
US6855823B2 (en) 2005-02-15
EP1200073A2 (en) 2002-05-02
JP4619595B2 (ja) 2011-01-26
IL146697A0 (en) 2002-07-25
HUP0202253A2 (hu) 2002-11-28
AU773304B2 (en) 2004-05-20
TR200200066T2 (tr) 2002-04-22
EP1200073B1 (en) 2007-01-10
DZ3209A1 (fr) 2001-01-11
US6759418B2 (en) 2004-07-06
ES2278619T3 (es) 2007-08-16
WO2001001972A3 (en) 2001-12-06
NZ515616A (en) 2004-05-28
DE60032905T2 (de) 2007-10-18
DK1200073T3 (da) 2007-05-07
NO20016246D0 (no) 2001-12-19
CN1230174C (zh) 2005-12-07
MXPA01012726A (es) 2002-07-02
HK1047036A1 (zh) 2003-02-07
US6566370B1 (en) 2003-05-20
HUP0202253A3 (en) 2003-12-29
DE60032905D1 (de) 2007-02-22
CA2378613A1 (en) 2001-01-11
WO2001001972A2 (en) 2001-01-11
AU5873200A (en) 2001-01-22
AR029373A1 (es) 2003-06-25
US7157582B2 (en) 2007-01-02
PT1200073E (pt) 2007-03-30
NO20016246L (no) 2002-03-04
HRP20020013A2 (en) 2003-08-31
SK112002A3 (en) 2003-05-02
US20030199546A1 (en) 2003-10-23
US20040192722A1 (en) 2004-09-30
MY133503A (en) 2007-11-30
KR20020024300A (ko) 2002-03-29
CN1359289A (zh) 2002-07-17
JP2003503449A (ja) 2003-01-28
BR0012175A (pt) 2002-03-05
EA004290B1 (ru) 2004-02-26
CZ20014488A3 (cs) 2003-01-15
CA2378613C (en) 2007-10-02

Similar Documents

Publication Publication Date Title
PE20010299A1 (es) DERIVADOS DE DECAHIDROISOQUINOLINA COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR iGLUR5
DE60042762D1 (de) Zwischenprodukte für die Herstellung von Harnstoffderivaten mit Muskarinrezeptor-antagonistischer Aktivität
PE1998A1 (es) DERIVADOS DE BENZO [g] QUINOLINA
EA200100755A1 (ru) 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
EA199800604A1 (ru) Производные 1-(1,2-дизамещенный пиперидинил)-4-замещенного пиперидинина как антагонисты рецепторов тахикинина
DK1177176T3 (da) Triarylsyrederivater som PPAR-receptorligander
DK0765314T3 (da) Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer
DE69006131D1 (de) Substituierte Chinazolinone als Angiotensin II-Antagonisten.
AR022230A1 (es) Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
TR200102839T2 (tr) LH agonistleri olarak faydalı bisiklik heteroaromatik bileşikler.
EA200101203A1 (ru) Производные пурина
AR029417A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
PE20050525A1 (es) Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1
PE20011314A1 (es) DERIVADOS DE N-(4-CARBAMIMIDOIL-FENIL)-GLICINA COMO INHIBIDORES DE LA FORMACION DE FACTORES DE COAGULACION Xa IXa Y TROMBINA
SE9904508D0 (sv) New compounds
PT1261602E (pt) Derivados imidazol-2-carboxamida como inibidores de cinase raf
TR200102489T2 (tr) 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması
ATE340795T1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
PT784054E (pt) Derivados de tetraidroquinoxalinadiona 1,2,3,4 e sua utilizacao como antagonistas do receptor glutamato
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
PE20021013A1 (es) Dihidropirimidinas-5-ciano sustituidos como agentes antiproliferativos
IL155965A0 (en) Pharmaceutical compositions containing an imidazole-5-carboxyclic acid derivative

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed